pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Bysanti
drug
save

milsaperidone

Marketedupdated 3mo ago
by $VNDA Vanda Pharmaceuticals Inc.
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • tagApproval4 co-mentions · 1 sources
  • tagSmall Molecule2 co-mentions · 1 sources

indications

investigational
SchizophreniaMajor Depression

all catalysts(0)

nothing on the calendar yet

Trials studying milsaperidone

  • phase3Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorderrecruitingn=500

Patent cliff

source: FDA Orange Book
first barrier falls
Mar 28, 2028
~1.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (63)

  • May 31, 2044method-of-use (U-4434)US 12478619
  • May 31, 2044method-of-use (U-4434)US 12478619
  • May 31, 2044method-of-use (U-4434)US 12478619
  • May 31, 2044method-of-use (U-4434)US 12478619
  • May 31, 2044method-of-use (U-4434)US 12478619
  • May 31, 2044method-of-use (U-4434)US 12478619
  • May 31, 2044method-of-use (U-4435)US 12478619
  • Dec 28, 2031method-of-use (U-4436)US 9074254
  • Dec 28, 2031method-of-use (U-4437)US 9074254
  • Dec 28, 2031method-of-use (U-4436)US 9074254
  • Dec 28, 2031method-of-use (U-4436)US 9074254
  • Dec 28, 2031method-of-use (U-4436)US 9074254
  • Dec 28, 2031method-of-use (U-4436)US 9074254
  • Dec 28, 2031method-of-use (U-4436)US 9074254
  • Feb 10, 2031method-of-use (U-4436)US 90742564.5y
  • Feb 10, 2031method-of-use (U-4436)US 90742564.5y
  • Feb 10, 2031method-of-use (U-4436)US 90742564.5y
  • Feb 10, 2031method-of-use (U-4437)US 90742564.5y
  • Feb 10, 2031method-of-use (U-4437)US 90742564.5y
  • Feb 10, 2031method-of-use (U-4437)US 90742564.5y
  • Feb 10, 2031method-of-use (U-4437)US 90742564.5y
  • Jan 16, 2031method-of-use (U-4437)US 90727424.4y
  • Jan 16, 2031method-of-use (U-4437)US 90727424.4y
  • Jan 16, 2031method-of-use (U-4437)US 90727424.4y
  • Jan 16, 2031method-of-use (U-4437)US 90727424.4y
  • Jan 16, 2031method-of-use (U-4437)US 90727424.4y
  • Jan 16, 2031method-of-use (U-4437)US 90727424.4y
  • Jan 16, 2031method-of-use (U-4437)US 90727424.4y
  • Dec 17, 2030method-of-use (U-4437)US 90742554.4y
  • Dec 17, 2030method-of-use (U-4436)US 90742554.4y
  • Dec 17, 2030method-of-use (U-4436)US 90742554.4y
  • Dec 17, 2030method-of-use (U-4436)US 90742554.4y
  • Dec 17, 2030method-of-use (U-4436)US 90742554.4y
  • Dec 17, 2030method-of-use (U-4436)US 90742554.4y
  • Dec 17, 2030method-of-use (U-4436)US 90742554.4y
  • Oct 28, 2030method-of-use (U-4437)US 89996384.2y
  • Oct 28, 2030method-of-use (U-4437)US 89996384.2y
  • Oct 28, 2030method-of-use (U-4437)US 89996384.2y
  • Oct 28, 2030method-of-use (U-4437)US 89996384.2y
  • Oct 28, 2030method-of-use (U-4437)US 89996384.2y
  • Oct 28, 2030method-of-use (U-4437)US 89996384.2y
  • Oct 28, 2030method-of-use (U-4437)US 89996384.2y
  • Jul 24, 2030method-of-use (U-4437)US 105632594.0y
  • Jul 24, 2030method-of-use (U-4437)US 105632594.0y
  • Jul 24, 2030method-of-use (U-4436)US 105632594.0y
  • Jul 24, 2030method-of-use (U-4436)US 105632594.0y
  • Jul 24, 2030method-of-use (U-4437)US 105632594.0y
  • Jul 24, 2030method-of-use (U-4437)US 105632594.0y
  • Jul 24, 2030method-of-use (U-4437)US 105632594.0y
  • Apr 5, 2030method-of-use (U-4436)US 91571213.7y
  • Apr 5, 2030method-of-use (U-4437)US 91571213.7y
  • Apr 5, 2030method-of-use (U-4436)US 91571213.7y
  • Apr 5, 2030method-of-use (U-4436)US 91571213.7y
  • Apr 5, 2030method-of-use (U-4436)US 91571213.7y
  • Apr 5, 2030method-of-use (U-4436)US 91571213.7y
  • Apr 5, 2030method-of-use (U-4436)US 91571213.7y
  • Mar 28, 2028method-of-use (U-4436)US 105704531.6y
  • Mar 28, 2028method-of-use (U-4436)US 105704531.6y
  • Mar 28, 2028method-of-use (U-4437)US 105704531.6y
  • Mar 28, 2028method-of-use (U-4436)US 105704531.6y
  • Mar 28, 2028method-of-use (U-4436)US 105704531.6y
  • Mar 28, 2028method-of-use (U-4436)US 105704531.6y
  • Mar 28, 2028method-of-use (U-4436)US 105704531.6y

News(0)

no news has mentioned this drug yet

brand
Bysanti
generic
milsaperidone
indication
Major Depressive Disorder
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 59m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?